Projected sales of select meningitis vaccines worldwide 2014-2028
In 2022, meningitis vaccine Bexsero is expected to generate some 938 million U.S. dollars in sales worldwide, making it the best-selling meningitis vaccine that year globally. By 2027, Menactra sales are projected to generate around 943 million U.S. dollars in sales, thereby surpassing Bexsero as leading vaccine. This graph illustrates the historic and projected sales of select leading meningitis vaccines worldwide from 2014 to 2028.
